FDA 483 - GlaxoSmithKline dba Human Genome Sciences Inc - April 26, 2013
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Human Genome Science, Inc.'s drug substance manufacturing facility in Rockville, Maryland, revealed significant deficiencies across multiple systems. Observations included inconsistent manufacturing processes, inadequate endotoxin controls, unvalidated media and buffer hold times, and an ineffective preventive maintenance program. The firm also demonstrated inadequate investigations, insufficient corrective and preventive actions, and a failure to follow or adequately document written procedures.
ID · 928ba880-1b8c-4356-831e-0f16d2c1f4dd